Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. NDAQ
9. TSCO
10. BE

Go back to Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs

Incyte (INCY) PT Lowered to $76 at RBC Capital

May 2, 2018 8:30 AM EDT

RBC Capital lowered its price target on Incyte (NASDAQ: INCY) to $76.00 (from $77.00) while maintaining a Outperform rating.

Analyst Brian Abrahams commented, "Jakafi continues to perform solidly and we believe provides a strong valuation foundation; while we acknowledge visibility on life cycle plans, later-stage pipeline... More

Incyte (INCY) Misses Q1 EPS by 2c

May 1, 2018 7:08 AM EDT

Incyte (NASDAQ: INCY) reported Q1 EPS of ($0.01), $0.02 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $382 million versus the consensus estimate of $390.05 million.

For earnings history and earnings-related data on Incyte (INCY) click here.

... More